Skip to main content

MiraLAX Disease Interactions

There are 3 disease interactions with MiraLAX (polyethylene glycol 3350).

Major

Laxatives (applies to MiraLAX) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc PROD (2001):
  5. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  6. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 6 references
Major

Laxatives (applies to MiraLAX) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet PROD (2001):
  5. "Product Information. Citrucel (methylcellulose)." SmithKline Beecham PROD (2001):
  6. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc PROD (2001):
  7. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  8. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 8 references
Major

PEG solutions (applies to MiraLAX) GI obstruction/perforation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Perforation, Ulcerative Colitis

The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.

References

  1. Raymond PL "Mallory-Weiss tear associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc 37 (1991): 410-1
  2. McBride MA, Vanagunas A "Esophageal perforation associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc 39 (1993): 856-7
  3. "Product Information. Golytely (polyethylene glycol 3350 with electrolytes)." Braintree
  4. "Product Information. GlycoLax (polyethylene glycol 3350)." DispenseXpress Inc (2016):
View all 4 references

MiraLAX drug interactions

There are 219 drug interactions with MiraLAX (polyethylene glycol 3350).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer